SCHEMBL19065207

SCHEMBL19065207

CC(C)(C)OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 1/20 0.55
▸ CTSL P07711 1/20 0.52
▸ CTSB P07858 1/20 0.52
▸ CTSS P25774 1/20 0.52
▸ CTSK P43235 1/20 0.52
▸ CPB1 P15086 1/20 0.51
▸ CPB2 Q96IY4 1/20 0.51
▸ SIRT2 Q8IXJ6 6/20 0.50
▸ SIRT1 Q96EB6 5/20 0.50
▸ SIRT3 Q9NTG7 3/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ PAX8 Q06710 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ MAPT P10636 1/20 0.49
▸ KLK7 P49862 1/20 0.49
▸ KLK5 Q9Y337 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23849707 1.00 FOLH1 (0.55) FOLH1CTSLCTSBCTSSCTSK
SCHEMBL29678907 0.95 FOLH1 (0.50) FOLH1CTSLCTSBCTSSCTSK
SCHEMBL29335184 0.92 CTSB (0.57) FOLH1CTSLCTSBCTSSCTSK
SCHEMBL4330584 0.91 FOLH1 (0.57) FOLH1SIRT2SIRT1SIRT3MAPT
SCHEMBL14680407 0.91 CPB1 (0.53) FOLH1CPB1CPB2SIRT2SIRT1
SCHEMBL14680621 0.90 CPB1 (0.46) FOLH1CTSLCTSBCTSSCTSK
SCHEMBL29679325 0.90 FOLH1 (0.67) FOLH1CPB1CPB2MEN1KMT2A
SCHEMBL18161563 0.90 FOLH1 (0.67) FOLH1CPB1CPB2MEN1KMT2A
SCHEMBL29465523 0.90 FOLH1 (0.67) FOLH1CPB1CPB2MEN1KMT2A
SCHEMBL4330583 0.90 FOLH1 (0.67) FOLH1CPB1CPB2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025095479-A1 NOVEL PROSTATE SPECIFIC MEMBRANE ANTIGEN LIGAND AND USE THEREOF 서울대학교병원 2025-05-08 — — WO disclosed
US-10688200-B2 Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy FIVE ELEVEN PHARMA INC. (US) 2020-06-23 — — US disclosed
US-20170189568-A1 UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY FIVE ELEVEN PHARMA INC. 2017-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189568-A1 UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY KLK3, FOLH1, UTS2R FOLH1 2/4885CTSL 930/4885CTSB 1877/4885
US-10688200-B2 Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy KLK3, FOLH1, UTS2R FOLH1 2/4885CTSL 930/4885CTSB 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback